Sinopharm Pharmaceutical: The application for approval of the listing of Lodechibai monoclonal antibody has been accepted by the National Medical Products Administration for the treatment of atopic dermatitis.

On July 8th, the new drug Ledechebai monoclonal antibody, a collaborative innovation between AstraZeneca and Kendy Biopharma, obtained acceptance for its market application by the National Medical Products Administration. It is used for the treatment of atopic dermatitis. Ledechebai monoclonal antibody is a fully humanized monoclonal antibody targeting IL-4R.